Anaemia correction in diabetic nephropathy: target haemoglobin values and cardiovascular complications


Citar

Texto integral

Resumo

Therapy strategy in anemia, associated with diabetic nephropathy, is discussed

Sobre autores

M Shestakova

S Martynov

Bibliografia

  1. Yoon K., Lee J.H., Kim J.W. et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368: 1681-1688.
  2. Diabetes Atlas, 4th edn. International Diabetes Federation. 2009.
  3. Сунцов Ю.И., Дедов И.И., Шестакова М.В. Скрининг осложнений сахарного диабета как метод оценки качества лечебной помощи больным. М. 2008.
  4. USRDS 2009 Annual Data Report. <http://www.usrds.org/>
  5. Astor B.C., Muntner P., Levin A. et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 2002; 162: 1401-1408.
  6. Thomas M., MacIsaac J., Tsalamandris C., et al. Anemia in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2004; 89 (9): 4359-4363.
  7. Thomas M., MacIsaac J., Tsalamandris C., et al. The burden of anemia in type 2 diabetes and role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant. 2004; 19: 1792-1797.
  8. Шестакова М.В., Мартынов С.А. Анемия при диабетической нефропатии: современная диагностика и новые технологии лечения. Методические рекомендации для врачей. Под редакцией академика РАН и РАМН И.И. Дедова. М. 2010.
  9. El-Achkar T.M., Ohmit S.E., McCullough P.A. et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67: 1483-1488.
  10. Шестакова М.В., Мартынов С.А., Ильин и др. Анемия при диабетической нефропатии: распространенность, клинические и патогенетические аспекты. Тер. арх. 2008, 6:. 41-47.
  11. Шестакова М.В. Дедов И.И. Сахарный диабет и хроническая болезнь почек. М.: МИА. 2009.
  12. Ishimura E., Nishizawa Y., Okuto S. et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J. Nephrol. 1998; 11: 83-86.
  13. Bosman D.R., Winkler A.S., Marsden J.T. et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001; 24 (3): 495-499.
  14. Thomas M. Anemia in diabetes: marker or mediator of microvascular disease. Nat. Clin. Pract. Nephrol. 2007; 1 (3): 20-30.
  15. Artunc F., Risler A. Serum erythropoietin concentrations and responses to anemia in patients with or without chronic kidney disease. Nephrol.Dial.Transplant. 2007; 22: 2900-2908.
  16. Fehr T., Ammann P., Garzoni D. et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia, Kidney Intern. 2004; 66: 1206-1244.
  17. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am. J. Kidney Dis. 2007; 50 471-530.
  18. Besarab A., Bolton W.K., Browne J.K. et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl. J. Med. 1998; 27: 584-590.
  19. Singh A.K., Szczech L., Tang K.L. et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New Engl. J. Med. 2006; 335: 2085-2098.
  20. Pfeffer M.A., Burdmann E.A., Chao-Yin Chen D. et al. A trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New Engl. J. Med. 2009; 361: 2019-2032.
  21. Unger E.F., Thompson A.M., Blank M.J., Temple R. erythropoiesis-Stimulating Agents - Time for a Reevaluation. New Engl. J. Med. 2010; 362: 189-192.
  22. Fishbane S., Berns J.S. Evidence and implications of haemoglobin cycling in anemia management. Nephrol. Dial. Transpl. 2007; 22: 2129-2132.
  23. Ebben J., Gilbertson D.T., Foley R.N. Collins J. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006; 1:1205-1210.
  24. Locatelli F, Aljama P, Barany P. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol. Dial. Transpl. 2004; 19 [Suppl 2]: ii1-ii47.
  25. National Kidney Foundation: K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia of chronic kidney disease. Am. J. Kidney Dis. 2006; 47 [Supl 3]: S1-S145.
  26. European Medicine Agency (EMEA). Epoetins and risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. Public statement (23 October 2007), EMEA/496188/2007.http://www.emea.europa.eu/pdfs/human/press/49618807en.pdf
  27. Anker S.D., Toto R. Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. Nephrol. Dial. Transplant. Plus. 2009; 2 [Suppl 1]: i3-i8.
  28. Locatelli F., Aljama P., Canaud B. et al. Target haemoglobin to aim with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. . Nephrol. Dial. Transplant. 2010; Advance Access published online on June 29. doi: 10.1093/ndt/gfq336
  29. Jelkmann W. Recombinant EPO production - points the nephrologist should now. Nephrol. Dial. Transplant. 2007; 22: 2749-2753.
  30. Klinger M., Arias M., Vargemezis V. et al. Efficacy of intravenous methoxy polyethylene glucole-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am. J. Kidney Dis. 2007; 50: 989-1000.
  31. Levin N.W., Fishbane S., Cañedo F.V. et al. Intravenous methoxy polyethylene glucole-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). The Lancet. 2007; 370;1415-1421.
  32. Sulowicz W., Locatelli F., Ryckelynck J-P. et al. Once-month subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin once to three times weekly. Clin. J. Am. Soc. Nephrol. 2007; 2:637-646.
  33. Macdougall I.C., Walker R., Provenzano R. et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of randomized clinical trial. Clin. J. Am. Soc. Nephrol. 2008; 3:337-347.
  34. Martínez-Castelao A., on Behalf of the CORDATUS Study. C.E.R.A. once every 4 weeks (Q4W) corrects anemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin weekly (QW) or once every 2 weeks (Q2W). Nephrol. Dial. Transplant. 2009; Vol.3 [Suppl.]: 3i219.
  35. Uriol M., Periañez L. and Munar M. Stable hemoglobin levels after a change of EPO to C.E.R.A in patients with chronic kidney disease not on dialysis. Nephrol. Dial. Transplant. 2009; Vol.3 [Suppl.]: iii216.
  36. Minutolo R., Mascia S., Vitiello S. et al. Conversion of darbepoetin (DA) to low doses of C.E.R.A. maintains hemoglobin (Hb) levels in non dialysis CKD patients. Nephrol. Dial. Transplant. 2009; Vol.3 [Suppl.]: 3i500.
  37. Куликов А.Ю., Аринина Е.Е. Анализ минимизации затрат на терапию нефрогенной анемии эритропоэзстимулирующими срудствами у пациентов с хронической болезнью почек, не получающих диализ. Фармакоэкономика. 2009; 4: 34-37.
  38. Dellanna F., Maduell F., De Cock E. on Behalf of the Participating Centres. Time saving associated with once- C.E.R.A.: A TIME AND MOTION STUDY in German and Spanish dialysis centres. Nephrol. Dial. Transplant. 2009; Vol.3 [Suppl.]: 3i506.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies